Skip to main content


Lung Cancer

Featured

Conference Coverage
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Conference Coverage
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Conference Coverage
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than…
Guideline Updates
NCCN released an update to its clinical practice guideline for SCLC, including modifications for supportive care and…
Guideline Updates
ASCO released an update to its guideline on systemic therapy for patients with stage IV NSCLC with driver alterations.
Back to Top